With only a couple of weeks to go before the most important annual meeting in the company's history, Vivus (VVUS) is showing some traction with its prescription numbers for anti-obesity drug Qsymia.
RBC analyst Michael J. Yee reports, that this is significantly lower when compared to Gilead's Sovaldi week 1 NRx of 151 and Harvoni week 1 NRx of 444. AbbVie's Viekira Pak's week 1 launch is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results